<DOC>
	<DOCNO>NCT01255319</DOCNO>
	<brief_summary>To evaluate feasibility efficacy condition regimen cyclophosphamide , fludarabine antithymocyte globulin ( CyFluATG ) allogeneic hematopoietic cell transplantation ( HCT ) patient low risk myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Cyclophosphamide , Fludarabine Antithymocyte Globulin Conditioning Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Conditioning therapy - Cytoxan 50 mg/kg/d d-3 -2 - Fludarabine 30 mg/m2 d-6 -2 - Antithymocyte globulin ( ATG ; ThymoglobulinÂ® ) 1.5 mg/kg/d ( HLA-matched sibling donor HCT ) 3.0 mg/kg/d ( alternative donor HCT ) - Methylpd 2 mg/kg/d d-4 -1 Mobilization harvest - G-CSF 10 mcg/kg/d s.c. d-3 0 - Harvest PBMCs 0 +1 Donor G PBMC infusion - Infuse G-PBMCs 0 d+1 . GVHD prophylaxis - Cyclosporine 1.5 mg/kg i.v . q 12 hr begin d-1 changed oral dosing ( twice i.v . dose ) oral intake possible . Tapered begin d+30 d+60 . - Methotrexate 15 mg/m2 i.v . d+2 , 10 mg/m2 i.v . d+4 d+7 Preemptive dose-escalating DLIs - Begin d+120 least 2 wks IST discontinuation . - Failure achieve full donor chimerism No evidence GVHD - CD3+ cell dose increment q 4 wks -+ cell dose : HLA-matched donor HCT ( 1 x 107/kg , 5 x 107/kg , 1 x 108/kg ) , HLA-matched unrelated donor HCT ( 1 x 106/kg , 5 x 106/kg , 1 x 107/kg ) , HLA-matched familial donor HCT ( 1 x 105/kg , 5 x 105/kg , 1 x 106/kg )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients low risk MDS ( bone marrow blast percentage &lt; 5 % ) Patients appropriate hematopoietic cell donor Adequate performance status ( Karnofsky score 70 ; see Appendix II ) Adequate hepatic renal function ( AST , ALT , bilirubin &lt; 3.0 x upper normal limit , creatinine &lt; 2.0 mg/dL ) . Adequate cardiac function ( left ventricular ejection fraction 40 % heart scan echocardiogram ) Signed date informed consent must obtain recipient donor . Presence significant active infection Presence uncontrolled bleed Any coexist major illness organ failure Patients diagnosis prior malignancy unless diseasefree least 5 year follow therapy curative intent ( except curatively treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia ) Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible Nursing woman , pregnant woman , woman childbearing potential want adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>MDS</keyword>
</DOC>